Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.64 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.64 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110581 | 1.00 | POLB (0.67) | POLBKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL1110694 | 1.00 | POLB (0.67) | POLBKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL1110760 | 1.00 | POLB (0.67) | POLBKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL1110606 | 0.90 | POLB (0.69) | POLBKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL3485680 | 0.90 | POLB (0.81) | POLBKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL1110642 | 0.89 | SRPK1 (0.80) | POLBKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL1110549 | 0.89 | ALDH1A1 (0.71) | KDRSRPK2SRPK1SRPK3ALDH1A1 | |
| SCHEMBL1110601 | 0.89 | ALDH1A1 (0.71) | KDRSRPK2SRPK1SRPK3ALDH1A1 | |
| SCHEMBL12765706 | 0.87 | ALDH1A1 (0.62) | POLBALDH1A1NPSR1LMNAMAPT | |
| SCHEMBL1110572 | 0.86 | KDR (0.57) | POLBKDRSRPK2SRPK1SRPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765941-B2 | Aniline derivative having anti-RNA viral activity | KINO PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765941-B2 | Aniline derivative having anti-RNA viral activity | KINO PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765941-B2 | Aniline derivative having anti-RNA viral activity | KINO PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20110059950-A1 | ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY | KINOPHARMA, INC. (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110059950-A1 | ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY | KINOPHARMA, INC. (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110059950-A1 | ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY | KINOPHARMA, INC. (JP) | 2011-03-10 | — | — | US | disclosed |
| EP-2279750-A1 | ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY | KinoPharma, Inc. (JP) | 2011-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059950-A1 | ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY | RNASEH1, SARS1, ADAR | POLB 167/4885KDR 3943/4885SRPK2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.